Regulations.gov document
Premarket Approval for BP180279, Avioq, Inc, VioOne™ HIV Profile™ Supplemental Assay
Other · FDA-2020-M-2094 · posted Oct 20, 2020
Key facts
| Document ID | FDA-2020-M-2094-0001 |
|---|---|
| Title | Premarket Approval for BP180279, Avioq, Inc, VioOne™ HIV Profile™ Supplemental Assay |
| Document type | Other |
| Subtype | Paperwork Packages |
| Agency | FDA |
| Docket | FDA-2020-M-2094 |
| Posted | Oct 20, 2020 |
| Comment period opens | Oct 20, 2020 |
At a glance
- None Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: